These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30104913)

  • 1. Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C.
    Yang CHT; Goel A; Ahmed A
    Adolesc Health Med Ther; 2018; 9():103-110. PubMed ID: 30104913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
    Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
    Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.
    Idilman R; Demir M; Aladag M; Erol C; Cavus B; Iliaz R; Koklu H; Cakaloglu Y; Sahin M; Ersoz G; Koksal İ; Karasu Z; Ozgenel M; Turan İ; Gunduz F; Ataseven H; Akdogan M; Kiyici M; Koksal AS; Akhan S; Gunsar F; Tabak F; Kaymakoglu S; Akarca US;
    J Viral Hepat; 2019 Jun; 26(6):666-674. PubMed ID: 30740820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C.
    Yang CHT; Yoo ER; Ahmed A
    J Clin Transl Hepatol; 2017 Mar; 5(1):59-66. PubMed ID: 28507928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
    Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?
    Premkumar M; Grover GS; Dhiman RK
    J Clin Exp Hepatol; 2017 Sep; 7(3):253-261. PubMed ID: 28970713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?
    Cervino L; Hynicka LM
    Ann Pharmacother; 2018 Nov; 52(11):1152-1157. PubMed ID: 29681166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    Tao T; Jiang X; Chen Y; Song Y
    Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
    Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
    Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.
    Yang YM; Choi EJ
    Ther Clin Risk Manag; 2017; 13():477-497. PubMed ID: 28442915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
    Younossi ZM; Stepanova M; Henry L; Han KH; Ahn SH; Lim YS; Chuang WL; Kao JH; Nguyen KV; Lai CL; Chan HL; Wei L
    J Viral Hepat; 2018 Dec; 25(12):1429-1437. PubMed ID: 29974665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
    J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis.
    Stokes W; Fenton C; Clement F; James M; Ronksley P; Tang KL
    Can J Gastroenterol Hepatol; 2017; 2017():6468309. PubMed ID: 28367429
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus.
    Inoue T; Goto T; Iio E; Matsunami K; Fujiwara K; Shinkai N; Matsuura K; Matsui T; Nojiri S; Tanaka Y
    Hepatol Res; 2018 Feb; 48(3):E203-E212. PubMed ID: 28834042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
    Abozeid M; Alsebaey A; Abdelsameea E; Othman W; Elhelbawy M; Rgab A; Elfayomy M; Abdel-Ghafar TS; Abdelkareem M; Sabry A; Fekry M; Shebl N; Rewisha E; Waked I
    Int J Infect Dis; 2018 Oct; 75():109-114. PubMed ID: 30077791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case report.
    Tadokoro T; Morishita A; Oura K; Fujita K; Mimura S; Sakamoto T; Nomura T; Tani J; Yoneyama H; Masaki T
    Exp Ther Med; 2018 Aug; 16(2):1026-1028. PubMed ID: 30116355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.